Literature DB >> 29378005

Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease.

Chelsea T Tiernan1, Elliott J Mufson2, Nicholas M Kanaan1,3, Scott E Counts1,4,3,5.   

Abstract

Although tau is the primary constituent of neurofibrillary tangles (NFTs), evidence suggests that its toxic moiety is oligomeric in Alzheimer disease (AD). In this regard, tau oligomers correlate more strongly with neuronal loss than NFTs and exhibit neurotoxicity in preclinical AD models. Here, we investigated the spatiotemporal progression of oligomeric tau accumulation within the highly vulnerable cholinergic neurons of the nucleus basalis of Meynert (nbM) in AD. Tissue from subjects who died with a clinical diagnosis of no cognitive impairment, mild cognitive impairment, or AD was immunostained with the tau oligomeric complex 1 (TOC1) antibody, a marker of tau oligomers, and p75NTR, a cholinergic cell marker. Stereological estimates revealed a significant increase in the number of TOC1 nbM immunopositive (+) neurons with a concomitant decrease in p75NTR+ nbM neurons during the transition from mild cognitive impairment to AD. Immunofluorescence identified TOC1+ neurons that colocalized with the pretangle tau marker phospho-Ser422, which persisted into late stage NFTs immunoreactive for MN423. Analysis of the nbM subfields revealed a topographical caudal to rostral gradient of TOC1+ neurons during disease progression. Taken together, these data suggest that toxic tau oligomers accumulate caudorostrally in selectively vulnerable nbM neurons during the onset of AD.
© 2018 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Basal forebrain; Mild cognitive impairment; Nucleus basalis of Meynert; Oligomeric; Phosphorylation; Tauopathy

Mesh:

Substances:

Year:  2018        PMID: 29378005      PMCID: PMC6251641          DOI: 10.1093/jnen/nlx120

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  102 in total

1.  The efficiency of systematic sampling in stereology--reconsidered.

Authors:  H J Gundersen; E B Jensen; K Kiêu
Journal:  J Microsc       Date:  1999-03       Impact factor: 1.758

2.  Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease.

Authors:  C R Harrington; E B Mukaetova-Ladinska; R Hills; P C Edwards; E Montejo de Garcini; M Novak; C M Wischik
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

3.  Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.

Authors:  Nicholas M Kanaan; Gerardo A Morfini; Nichole E LaPointe; Gustavo F Pigino; Kristina R Patterson; Yuyu Song; Athena Andreadis; Yifan Fu; Scott T Brady; Lester I Binder
Journal:  J Neurosci       Date:  2011-07-06       Impact factor: 6.167

Review 4.  Tau oligomers and tau toxicity in neurodegenerative disease.

Authors:  Sarah M Ward; Diana S Himmelstein; Jody K Lancia; Lester I Binder
Journal:  Biochem Soc Trans       Date:  2012-08       Impact factor: 5.407

5.  Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis.

Authors:  P J Whitehouse; D L Price; A W Clark; J T Coyle; M R DeLong
Journal:  Ann Neurol       Date:  1981-08       Impact factor: 10.422

6.  Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.

Authors:  Kristina R Patterson; Christine Remmers; Yifan Fu; Sarah Brooker; Nicholas M Kanaan; Laurel Vana; Sarah Ward; Juan F Reyes; Keith Philibert; Marc J Glucksman; Lester I Binder
Journal:  J Biol Chem       Date:  2011-05-06       Impact factor: 5.157

7.  Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.

Authors:  Cristian A Lasagna-Reeves; Diana L Castillo-Carranza; Urmi Sengupta; Jose Sarmiento; Juan Troncoso; George R Jackson; Rakez Kayed
Journal:  FASEB J       Date:  2012-01-17       Impact factor: 5.191

8.  Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments.

Authors:  T Kimura; T Ono; J Takamatsu; H Yamamoto; K Ikegami; A Kondo; M Hasegawa; Y Ihara; E Miyamoto; T Miyakawa
Journal:  Dementia       Date:  1996 Jul-Aug

9.  Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells.

Authors:  Marija Usenovic; Shahriar Niroomand; Robert E Drolet; Lihang Yao; Renee C Gaspar; Nathan G Hatcher; Joel Schachter; John J Renger; Sophie Parmentier-Batteur
Journal:  J Neurosci       Date:  2015-10-21       Impact factor: 6.167

10.  Hyperphosphorylation-induced tau oligomers.

Authors:  Khalid Iqbal; Cheng-Xin Gong; Fei Liu
Journal:  Front Neurol       Date:  2013-08-15       Impact factor: 4.003

View more
  10 in total

1.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

Review 2.  Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.

Authors:  Donald E Moss; Ruth G Perez
Journal:  Curr Alzheimer Res       Date:  2021       Impact factor: 3.498

3.  Mitochondrial oxidative stress contributes to the pathological aggregation and accumulation of tau oligomers in Alzheimer's disease.

Authors:  Fang Du; Qing Yu; Nicholas M Kanaan; Shirley ShiDu Yan
Journal:  Hum Mol Genet       Date:  2022-08-17       Impact factor: 5.121

4.  Three-repeat and four-repeat tau isoforms form different oligomers.

Authors:  Hedieh Shahpasand-Kroner; Jennifer Portillo; Carter Lantz; Paul M Seidler; Natalie Sarafian; Joseph A Loo; Gal Bitan
Journal:  Protein Sci       Date:  2022-01-07       Impact factor: 6.993

5.  HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease.

Authors:  L Mahady; M Nadeem; M Malek-Ahmadi; K Chen; S E Perez; E J Mufson
Journal:  Neuropathol Appl Neurobiol       Date:  2018-10-28       Impact factor: 8.090

6.  Fungally Derived Isoquinoline Demonstrates Inducer-Specific Tau Aggregation Inhibition.

Authors:  David J Ingham; Bryce R Blankenfeld; Shibin Chacko; Chamani Perera; Berl R Oakley; Truman Christopher Gamblin
Journal:  Biochemistry       Date:  2021-05-19       Impact factor: 3.162

Review 7.  Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognition.

Authors:  Paul Denver; Paula L McClean
Journal:  Neural Regen Res       Date:  2018-10       Impact factor: 5.135

Review 8.  Recent Trends in the Management of Alzheimer's Disease: Current Therapeutic Options and Drug Repurposing Approaches.

Authors:  Rakesh K Singh
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

9.  Cholinergic receptor binding in unimpaired older adults, mild cognitive impairment, and Alzheimer's disease dementia.

Authors:  David L Sultzer; Aaron C Lim; Hailey L Gordon; Brandon C Yarns; Rebecca J Melrose
Journal:  Alzheimers Res Ther       Date:  2022-02-07       Impact factor: 8.823

Review 10.  Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?

Authors:  Donald E Moss
Journal:  Int J Mol Sci       Date:  2020-05-13       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.